3SBio Inc. - Product Pipeline Review - 2012

Global Markets Direct, August 2012, Pages: 51

3SBio Inc. – Product Pipeline Review – 2012

Summary

Global Markets Direct’s pharmaceuticals report, “3SBio Inc. - Product Pipeline Review - 2012” provides data on the 3SBio Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, 3SBio Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from 3SBio Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- 3SBio Inc. - Brief 3SBio Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of 3SBio Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of 3SBio Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the 3SBio Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate 3SBio Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of 3SBio Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the 3SBio Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with 3SBio Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of 3SBio Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of 3SBio Inc.; 3SBio Inc. - Key Therapeutics; 3SBio Inc. - Pipeline Overview and Promising Molecules; 3SBio Inc. - News; 3SBio Inc. - Latest Updates; 3SBio Inc. - Pipeline; 3SBio Inc. - Discontinued/Dormant Projects

2
List of Tables 4
List of Figures 4
3SBio Inc. Snapshot 5
3SBio Inc. Overview 5
Key Information 5
Key Facts 5
3SBio Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
3SBio Inc. – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
3SBio Inc. – Pipeline Products Glance 11
3SBio Inc. – Late Stage Pipeline 11
Registration Filed Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
3SBio Inc. Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
3SBio Inc. – Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
3SBio Inc. – Drug Profiles 16
Feraheme 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Nephoxil 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
NuLeusin 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
SSS08 Vaccine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Uricase-PEG 20 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Voclosporin 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
3SBio Inc. – Recent Pipeline Updates 26
3SBio Inc. - Dormant Projects 32
3SBio Inc. – Company Statement 33
3SBio Inc. – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
3SBio Inc., Recent Developments 35
3SBio Inc.- Press Release 35
Aug 15, 2012: Apexigen's Partner 3SBio Files Investigational New Drug Application For APX001 With SFDA 35
Jan 20, 2009: 3SBIO Files For SFDA Approval For TPIAO Label Extension For Treatment Of ITP 35
Financial Deals Landscape 37
3SBio Inc., Deals Summary 37
3SBio Inc., Pharmaceuticals & Healthcare, Deal Details 38
Asset Transactions 38
3SBio Acquires Rights Of Pegsitacase From EnzymeRx 38
Partnerships 40
3SBio Enters Into Joint Venture Agreement With DaVita For Dialysis Treatment 40
Isotechnika Pharma Enters Into Strategic Alliance With 3SBio 41
3SBio Enters Into Co-Development Agreement With Ascentage Pharma 43
Licensing Agreements 44
3SBio Enters Into Licensing Agreement With Panacor Bioscience 44
3SBio Enters Into Licensing Agreement With AMAG Pharma For Ferumoxytol 45
3SBio Enters Into Licensing Agreement With Epitomics 47
Equity Offering 48
3SBio Completes IPO Of $119.05 Million 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables
3SBio Inc., Key Information 5
3SBio Inc., Key Facts 5
3SBio Inc. – Pipeline by Indication, 2012 8
3SBio Inc. – Pipeline by Stage of Development, 2012 9
3SBio Inc. – Monotherapy Products in Pipeline, 2012 10
3SBio Inc. – Filed, 2012 11
3SBio Inc. – Phase III, 2012 12
3SBio Inc. – Phase II, 2012 13
3SBio Inc. – Phase I, 2012 14
3SBio Inc. – Pre-Clinical, 2012 15
3SBio Inc. – Recent Pipeline Updates, 2012 26
3SBio Inc. - Dormant Developmental Projects,2012 32
3SBio Inc., Other Locations 34
3SBio Inc., Subsidiaries 34
3SBio Inc., Deals Summary 37
3SBio Acquires Rights Of Pegsitacase From EnzymeRx 38
3SBio Enters Into Joint Venture Agreement With DaVita For Dialysis Treatment 40
Isotechnika Pharma Enters Into Strategic Alliance With 3SBio 41
3SBio Enters Into Co-Development Agreement With Ascentage Pharma 43
3SBio Enters Into Licensing Agreement With Panacor Bioscience 44
3SBio Enters Into Licensing Agreement With AMAG Pharma For Ferumoxytol 45
3SBio Enters Into Licensing Agreement With Epitomics 47
3SBio Completes IPO Of $119.05 Million 48

List of Figures
3SBio Inc. – Pipeline by Indication, 2012 7
3SBio Inc. – Pipeline by Stage of Development, 2012 9
3SBio Inc. – Monotherapy Products in Pipeline, 2012 10

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• eBay - Strong Execution
• Ixia - Company Analysis
• Amazon - Point of Realization in 2013?
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• Analysis of Google Inc